526. Implementation of Use of Monoclonal Antibody Therapy in a Large Academic Center for the Outpatient Treatment of Covid-19: Impact on 30 Day Hospitalization Rates, ED Visits and Death

BACKGROUND: Monoclonal Antibody Therapy (MAbs) has been shown to reduce rates of ED visits and hospitalizations in patients at risk for severe Covid-19 infection in clinical trials. Since November, three Mabs received emergency use authorization: Bamlanivimab (Bam), Bamlanivimab/Etesevimab (Bam/Ete)...

Descripción completa

Detalles Bibliográficos
Autores principales: Bhimani, Azra, Srinivasan, Vinay, Weinstein, Stacey, Clemons, Nathan, Batiste, Quanna, Yang, Shangxin, Garner, Omai, Vijayan, Tara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Poster Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644664/
http://dx.doi.org/10.1093/ofid/ofab466.725

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644664/
http://dx.doi.org/10.1093/ofid/ofab466.725

Ejemplares similares